Compare BHP Billiton Limited (BHP) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BHP Billiton Limited vs Novo Nordisk A/S — how do they compare? BHP Billiton Limited trades at $84.72 (market cap $205.61B), while Novo Nordisk A/S trades at $49.08 (market cap $214.94B). The key difference: BHP Billiton Limited and Novo Nordisk A/S are close in size by market cap, and Novo Nordisk A/S pays the higher dividend (3.67%). Which is the better fit depends on your goals.
| BHP | NVO | |
|---|---|---|
Market Cap | $205.61B | $214.94B |
Sector | Basic Materials | Health |
52-Week High | $93.15 | $71.70 |
52-Week Low | $50.37 | $35.29 |
Enterprise Value | $219.82B | $233.91B |
Dividend Yield | 3.15% | 3.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BHP trades at $81.37, down 0.38% with neutral technical signals. The stock shows strong profitability with 18.97% net margin and 20.13% ROE, though recent earnings missed expectations in Q4 2025. Cash flow remains positive with $75M net in 2024, while debt-to-asset ratio increased to 17.65%. Recent news highlights labor strikes and a $2.3B writedown at the Jansen potash project.
Outlook is mixed: solid fundamentals and analyst buy ratings (22.58%) support potential upside, but near-term risks from operational disruptions and cost overruns may pressure shares. Investors should weigh strong cash generation against execution challenges under new leadership.
Novo Nordisk (NVO) trades at $49.28, down 0.4% on the day, with strong technical momentum indicated by bullish moving averages and a neutral RSI near 63. The company demonstrates robust fundamentals with a P/E of 11.83, net income margin of 37.2%, and consistent earnings beats in recent quarters. Recent news highlights competitive strength in GLP-1 drugs, including Wegovy pill adoption outpacing Eli Lilly's offering.
Outlook remains positive given analyst consensus of 57.9% buy ratings and intrinsic value estimates near $90, though risks include prescription slowdown concerns and rising debt-to-asset ratios. The stock presents a growth opportunity in pharmaceuticals with manageable near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BHP Billiton Limited
BHP Group Limited operates as a mining company. The Company engages in the exploration, development, production, and processing of iron ore, metallurgical coal, and copper. BHP Group serves customers worldwide.
Read more on BHP →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
